Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Does Azithromycin Cause QT Prolongation in Hospitalized Patients With Severe Community Acquired Pneumonia?

This study has been completed.
Information provided by (Responsible Party):
HaEmek Medical Center, Israel Identifier:
First received: March 11, 2012
Last updated: August 30, 2016
Last verified: August 2016
The macrolide group of antibiotics can cause QT prolongation, and endanger the patient with life threatening arrythmias. QT prolongation caused by Azythromycin, a relatively new macrolide, is extremely rare, and was not reported in clinical trials. Our hypothesis is that patients hospitalized with severe community acquired pneumonia, usually with multiple comorbid conditions will have a higher rate of QT prolongation, compared to the clinical trials published


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Does Azithromycin Cause QT Prolongation in Hospitalized Patients With Severe Community Acquired Pneumonia?

Resource links provided by NLM:

Further study details as provided by HaEmek Medical Center, Israel:

Primary Outcome Measures:
  • Corrected QT segment of ECG [ Time Frame: Daily, at estimated peak antibiotic level, during index hospitalization ] [ Designated as safety issue: Yes ]

Enrollment: 148
Study Start Date: March 2012
Study Completion Date: May 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Detailed Description:
Patients hospitalized with community aquired pneumonia will have their corrected QT measured daily during antibiotic therapy. Concomittant medications and electrolyte abnormalities that cause prolonged QT will be recorded

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients hospitalized with severe community aquired pneumonia treated with azithromycin

Inclusion Criteria:

  • Severe community acquired pneumonia
  • treated with azithromycin
  • age over 18 years

Exclusion Criteria:

  • Azithromycin initiated before hospitalization
  • technically undecipherable ECG
  • Permanent pacemaker
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01553734

HaEmek Medical Center
Afula, Israel, 18101
Sponsors and Collaborators
HaEmek Medical Center, Israel
Principal Investigator: Lee H Goldstein, MD Haemek Medical Center, Afula, Israel
  More Information

Responsible Party: HaEmek Medical Center, Israel Identifier: NCT01553734     History of Changes
Other Study ID Numbers: EMC-130-11 
Study First Received: March 11, 2012
Last Updated: August 30, 2016
Health Authority: Israel: Ministry of Health
Individual Participant Data  
Plan to Share IPD: No

Keywords provided by HaEmek Medical Center, Israel:
QT prolongation
ECG changes

Additional relevant MeSH terms:
Long QT Syndrome
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Heart Defects, Congenital
Cardiovascular Abnormalities
Congenital Abnormalities
Pathologic Processes processed this record on October 25, 2016